scholarly journals A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

2021 ◽  
Author(s):  
A. Brufsky ◽  
S.B. Kim ◽  
Ž. Zvirbule ◽  
A. Eniu ◽  
J. Mebis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Randomized Trial ◽  
Phase Ii ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Locally Advanced ◽  
Line Treatment ◽  
First Line ◽  
Primary Analysis ◽  
First Line Treatment

IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS1104-TPS1104 ◽  
Author(s):  
Leisha A. Emens ◽  
Sylvia Adams ◽  
Sherene Loi ◽  
Andreas Schneeweiss ◽  
Hope S. Rugo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Randomized Trial ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Phase Iii ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document